drugset / Trial / NCT02525237
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-08
- Completion
- 2017-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | S-1 | Small molecule | 40 mg/m2 | Oral |